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ABSTRACT: Fragment-based lead discovery (FBLD) holds great promise for drug
discovery, but applications to G protein-coupled receptors (GPCRs) have been
limited by a lack of sensitive screening techniques and scarce structural information.
If virtual screening against homology models of GPCRs could be used to identify
fragment ligands, FBLD could be extended to numerous important drug targets and
contribute to eﬃcient lead generation. Access to models of multiple receptors may
further enable the discovery of fragments that bind speciﬁcally to the desired target.
To investigate these questions, we used molecular docking to screen >500 000
fragments against homology models of the A3 and A1 adenosine receptors (ARs) with
the goal to discover A3AR-selective ligands. Twenty-one fragments with predicted
A3AR-speciﬁc binding were evaluated in live-cell ﬂuorescence-based assays; of eight
veriﬁed ligands, six displayed A3/A1 selectivity, and three of these had high aﬃnities ranging from 0.1 to 1.3 μM. Subsequently,
structure-guided fragment-to-lead optimization led to the identiﬁcation of a >100-fold-selective antagonist with nanomolar
aﬃnity from commercial libraries. These results highlight that molecular docking screening can guide fragment-based discovery
of selective ligands even if the structures of both the target and antitarget receptors are unknown. The same approach can be
readily extended to a large number of pharmaceutically important targets.
■ INTRODUCTION
Fragment-based lead discovery (FBLD) has rapidly developed
into one of the main strategies for early-phase drug develop-
ment. Drug discovery programs driven by FBLD have quickly
progressed into clinical trials, and fragment screens have been
applied successfully to targets for which high-throughput
screening (HTS) approaches have failed.1 The main diﬀerence
between HTS and FBLD is that the latter approach initially
focuses on the identiﬁcation of ligands that are less than half the
size of a drug. Because of the lower complexity of fragments
compared with drug-like molecules, screens of chemical
libraries with hundreds to thousands of compounds cover
suﬃcient portions of chemical space to identify ligands. This
makes FBLD an attractive alternative to HTS, which may
require screening of libraries that are several orders of
magnitude larger to identify lead compounds.1 As fragments
are typically low-aﬃnity ligands, a major challenge in FBLD has
been the development of sensitive screening techniques. This
has been particularly problematic for membrane proteins, which
include important drug targets such as G protein-coupled
receptors (GPCRs) and ion channels.2 Recently, fragment
screens using NMR-,3 surface plasmon resonance (SPR)-,4 and
ﬂuorescence-based5 methods have successfully been applied to
GPCRs, making it feasible to begin utilizing FBLD for the large
number of important drug targets in this superfamily.6
The weakly binding ligands that emerge from fragment
screens occupy subpockets on the protein surface and have to
be combined or grown to generate potent lead compounds.7
Fragments typically lack speciﬁcity because of their low
molecular complexity,8 which makes it a challenge to achieve
selectivity for the desired target.9 The identiﬁcation of selective
lead compounds is of particular importance for GPCRs, as
many subtypes recognize the same ligands, resulting in
orthosteric binding sites with a high degree of homology. For
many soluble targets, FBLD can often take advantage of the
relative ease of generating crystal structures for protein−
fragment complexes, which can provide invaluable information
in ligand optimization.10 Recent breakthroughs in this area have
resulted in atomic-resolution crystal structures for GPCRs,11
and in a few cases it has even been feasible to resolve the
binding modes of fragment ligands.12 On the basis of the
detailed information provided by crystal structures, virtual
screening has been used successfully to discover fragment
ligands with high hit rates for soluble proteins9,13 and, more
recently, GPCRs.14,15 However, as the determination of GPCR
crystal structures still requires considerable experimental eﬀort,
in silico fragment screening remains limited to the small
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number of crystallized targets. On the other hand, if homology
models based on available templates could be utilized in FBLD,
structure-guided discovery and optimization of fragments could
be applied to a large fraction of the GPCR superfamily, but this
has rarely been attempted.16,17 Moreover, access to models of
several receptor subtypes may also enable the eﬃcient design of
selective leads, which is crucial in drug development to avoid
adverse eﬀects caused by interactions with unintended targets.
In this work, we explored the prospect of using in silico
screening of commercially available libraries to identify and
optimize subtype-selective fragments targeting GPCRs of
unknown structure. The target GPCR, the A3 adenosine
receptor (A3AR), belongs to a family of four human receptors
that recognize adenosine and was selected for its potential as a
drug target for a wide range of diseases, including glaucoma
(antagonists), cancer (agonists), and asthma (antagonists).18,19
As interactions with the closely related A1 adenosine receptor
(A1AR) may cause cardiac complications
20 (A1 agonists) and
lead to increased risks for seizure and stroke (A1 antagonists),
19
fragments that selectively bind to the A3AR over the A1AR were
sought. We generated models of the A3AR and A1AR based on
a crystal structure of the A2AAR and carried out molecular
docking screens of >0.5 million fragments against both
receptors. Fragments predicted to bind preferentially to the
A3AR over the A1AR were evaluated in a live-cell ﬂuorescence-
based high-content screening assay. To further probe the utility
of our approach, the A1- and A3AR homology models were also
used to guide the optimization of fragment potency and
selectivity. On the basis of our results, the feasibility of
structure-guided FBLD for GPCRs of unknown structure will
be discussed.
■ RESULTS
Homology Modeling of the A3 and A1 Adenosine
Receptors. As no crystal structures of the A3- and A1AR were
available, protocols for the generation of homology models for
the target and antitarget receptors were developed. A structure
of the A3AR binding site was required in order to predict
ligands, and modeling of the A1AR was essential for assessing
the selectivity by comparing diﬀerences between the predicted
binding energies from molecular docking for the two subtypes.
The protocol for optimization of the homology models is
summarized in Figure 1.
Homology modeling of the A3- and A1AR was based on a
high-resolution crystal structure of the closely related A2AAR,
21
which has 51% and 59% sequence identity to the A3- and A1AR,
respectively, in the transmembrane region (Figure S1). To
identify a suitable model of the A3AR, a ligand-guided
homology modeling approach was employed.22,23 Initially,
1000 A3AR homology models were generated, and the 300
structures with the highest model quality, as judged by their
DOPE scores,24 were further evaluated. Docking screens of two
sets of compounds were used to assess the ability of the A3AR
models to recognize known ligands. One set of lead-like ligands
and one set of >50-fold subtype-selective A3AR ligands were
compiled, and 50 decoys per ligand were added to each
compound set.25 The lead-like set was ﬁrst docked to the 300
A3AR homology models using DOCK3.6.
26 The ability of a
model to enrich ligands over decoys was assessed on the basis
of a receiver operator characteristic (ROC) curve and
quantiﬁed using the adjusted logarithm of area under the
curve (aLogAUC) metric.27 A positive aLogAUC value for a
given model indicates that enrichment of ligands over decoys is
better than random. The 50 models with the best aLogAUC
values, ranging from 31 to 39, were taken forward for further
assessment (Figures 1 and S2a). These binding site models
displayed strong enrichment of known ligands and ranked them
26-fold better than expected from random selection in the top
1% of the screened database. The set of A3AR-selective ligands
together with decoys was then docked to the 50 remaining
models. The ligand enrichments for these models were again
signiﬁcantly better than random (aLogAUC = 11−41). The
homology model with the best enrichment of lead-like and
A3AR-selective compounds was also judged to produce binding
modes that agreed with those observed for ligands in available
crystal structures of the A2AAR
21 (Figure 2a), and this model
was taken forward for prospective screening.
As in the case of the A3AR, 1000 homology models were also
generated for the A1AR, and retrospective screens of lead-like
ligands along with decoys against 300 structures were carried
out to identify suitable binding site structures. The resulting
enrichments were again signiﬁcantly better than random for a
majority of the models (Figure S2b). The A3AR-selective ligand
set was then docked to the 50 best models. However, in
contrast to the A3AR modeling protocol, the goal was to
identify A1AR structures that did not enrich these compounds
to bias the prospective docking screen toward the discovery of
Figure 1. Summary of the modeling protocol for the A3- and A1AR.
Ligand-guided homology modeling was used to identify homology
models suitable for virtual screening. In a ﬁrst step, 1000 homology
models for each receptor based on an A2AAR crystal structure were
generated. Docking screens against the 300 homology models with the
best model quality scores were then used to identify 50 binding site
structures of the A3- and A1AR with the ability to recognize known
(lead-like) ligands. Molecular docking of A3AR-selective ligands to the
50 models was used to guide the selection of a single structure for the
A3AR subtype and an ensemble of 10 A1AR structures, which were
used in the prospective screens. The A1-, A2A-, and A3AR are depicted
in cyan, green, and white, respectively.
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A3AR-selective ligands, i.e., the models with the lowest
aLogAUC values were considered. The enrichment of A3AR-
selective ligands was signiﬁcantly worse for the A1AR model
compared with the A3AR model, indicating that subtype
selectivity was captured (Figure S2b). However, to ensure that
a ligand of the target receptor will not bind to the antitarget, it
is not suﬃcient to screen a single structure, as the compound
may be recognized by a diﬀerent binding site conformation. To
take this into consideration, 10 diﬀerent models representing
diﬀerent shapes of the orthosteric site were selected on the
basis of the quality of the binding poses of known A1AR ligands
and their lower enrichment of A3AR-selective ligands (Figures
S2b and S3).
Analysis of the A1- and A3AR models revealed highly similar
orthosteric sites, with close to 50% identical amino acid
residues in the binding pocket. The predicted binding modes
for A3AR-selective ligands provided insights into structural
elements that could be exploited to achieve subtype selectivity
(Figure 2). One such nonconserved region was identiﬁed in the
vicinity of Val1695.30 (the superscript denotes the Ballesteros−
Weinstein numbering28) in the A3AR model. The A1AR has
Glu1725.30 in the same position and was predicted to form a salt
bridge to His2646.66, which is also conserved in the template
A2AAR crystal structure.
21 This diﬀerence resulted in a more
enclosed and polar environment at the top of the orthosteric
site of the A1AR compared with the A3AR. For the A3AR,
Val1695.30 and Ile2536.58 (Glu and Thr, respectively, in the
A1AR) created a more hydrophobic environment in this region.
The potential importance of these residues for selectivity was
further supported by evidence that several docked A3AR-
selective ligands occupied this subpocket with bulky groups.
There were also more deeply buried nonconserved residues in
the orthosteric site, e.g., Ser2476.52 of the A3AR. As the A1AR
had His2516.52 in the corresponding position, this created an
additional subpocket in the A3AR model that was occluded in
the antitarget (Figure 2).
Docking Screen for A3AR-Selective Fragments. After
deriving homology models of both the A1- and A3AR subtypes,
we turned to prospective screening for novel A3AR fragment
ligands. We were particularly interested in investigating whether
a structure-based approach enables prediction of selective
scaﬀolds, as ligands with speciﬁcity for the targets are typically
not expected to emerge from fragment screening campaigns.9
More than 0.5 million commercially available fragments from
the ZINC database29 were screened against the A3AR structure
and the ensemble of 10 A1AR models using DOCK3.6.
26 Each
compound in the library was docked in thousands of
orientations, resulting in a total of ﬁve billion predicted
receptor−fragment complexes. A fragment was considered to
be selective for the A3AR if it was top-ranked for the model of
this receptor and the diﬀerence in docking rank was >10 000
positions worse for all of the screened A1AR models. On the
basis of this criterion, only 27 of the 500 top-ranked
compounds for the A3AR were selective, which likely reﬂected
the high degree of similarity between the binding sites of these
AR subtypes. In addition, as only fragments were considered,
there were few compounds that could form the key interactions
required for ligand binding and extend into nonconserved
regions. The 4000 top-ranked compounds from the A3AR
screen (0.8% of the screened database) had to be considered to
identify 500 fragments that fulﬁlled the selectivity criterion. A
large fraction of the 500 molecules interacted with Asn2506.55
and typically extended into at least one nonconserved region of
the orthosteric site. Predicted binding poses were also inspected
for the 10 A1AR models to ensure that the same receptor−
ligand interactions could not be achieved for the antitarget.
After visual inspection, a diverse set of 21 compounds
(compounds 1−21; Table S1) were selected for experimental
evaluation on the basis of their shape complementarity to the
A3AR binding site, taking into account neglected terms in the
docking scoring function as described previously.14,22,30 These
compounds were also screened for substructures present in the
set of previously characterized pan-assay interference com-
pounds (PAINS)31 and did not contain any of these motifs.
The average ranks for the selected compounds were 2293 for
the A3AR and 29 579 for the A1AR, with a median rank
diﬀerence of 24 319.
The predicted ligands were evaluated using a live-cell
ﬂuorescence-based competition assay at the A3- and A1AR.
Figure 2. Structural basis of subtype selectivity. (a) An A3AR-selective
ligand docked to an A3AR homology model.
37 (b) Alignment of A1-
and A3AR homology models. Key residues for binding and selected
nonconserved residues are depicted in white and cyan sticks for the A3-
and A1AR, respectively. (c) Schematic representation of the A3- and
A1AR binding sites. The black solid line outlines the binding site of the
A3AR, and the A1AR is represented in cyan.
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This assay uses an image-based approach to measure the ability
of each compound to compete with the binding of a xanthine
amine congener-based ﬂuorescent ligand, CA200645.5 Known
A3AR-selective (MRS1220) or A1AR-selective (DPCPX)
antagonists were tested on both A3AR- and A1AR-expressing
cells to conﬁrm that each cell line had the expected
pharmacology for the given receptor (Figure S4). Compounds
were initially evaluated at a single concentration (typically 1
mM), and the nine compounds that displaced the binding of
CA200645 at the A3AR to within 15% of that achieved by the
reference A3AR-selective compound MRS1220 (1 μM) were
taken forward for further evaluation (Table S1 and Figure S5).
Full concentration−response curves were generated for
compounds 1−9 (Figure S6). The Ki values for compounds
1−4 ranged from 0.12 to 1.3 μM at the A3AR. Compounds 5−
8 were less potent A3AR ligands, and their Ki values could not
be precisely determined. Compound 9 was found to interfere
with the assay and was therefore excluded from further
consideration. The eight identiﬁed A3AR ligands corresponded
to a hit rate of 38%, and notably, six of them displayed the
desired selectivity. No compounds with signiﬁcant activity
displayed higher aﬃnity for the A1 subtype over the A3 subtype
(Tables 1 and S1). The four most potent compounds (1−4)
were further examined, and their predicted binding modes are
shown in Figures 3 and S7. Whereas compound 3 displayed
similar aﬃnities for the two subtypes, compounds 1, 2, and 4
were remarkably selective for the A3AR with Ki ratios ranging
from 24 to >38. In addition, the ligand eﬃciencies for the four
most potent fragments (calculated as LE = −(RT ln Ki)/N,
where N is the number of ligand heavy atoms) varied between
0.47 and 0.62 kcal mol−1 atom−1, which indicated that they
were promising starting points for optimization.32
The chemical novelty of compounds 1−4 was assessed on
the basis of their two-dimensional similarities to all A1-, A2A-,
Table 1. Binding Aﬃnities for the Four Most Potent Fragments from the Docking Screen; Ki Values Were Obtained from the
Fluorescence-Based Competition Binding Assay in Cells Expressing the A3AR or A1AR
aRank of the compound in the docking screen of >0.5 million fragments from the ZINC database. bValues represent mean ± standard error of the
mean (SEM) from n separate experiments performed in duplicate. cFold selectivity represents the Ki value at the A1AR divided by the Ki value at the
A3AR.
dCompound 2 could not be tested at concentrations higher than 100 μM because of solubility issues. The pKi value was derived by assuming
that higher concentrations would displace binding to nonspeciﬁc levels.
Figure 3. Predicted receptor−ligand complexes for two discovered ligands. The binding modes predicted by molecular docking for compounds (a) 1
and (b) 2 in the A3AR model are shown. The A3AR backbone is depicted as a white cartoon, and carbon atoms of key residues are shown as white
sticks. The atoms of the ligand are shown as sticks with carbon atoms in orange.
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A2B-, and A3AR ligands in the ChEMBL20 database. Similarity
was quantiﬁed using the Tanimoto coeﬃcient (Tc) calculated
with extended connectivity ﬁngerprints, maximum distance 4
(ECFP4). The maximal Tc value of 1 is obtained if there is an
identical known ligand, whereas small values indicate low
similarity to previously characterized compounds. The
calculated Tc values for the identiﬁed ligands ranged from
0.28 to 0.4 (Table S2). Compounds 2−4 were judged to be
dissimilar to the most similar AR ligands, and these molecules
also had Tc values of <0.4, which is typical for novel
chemotypes.33 Compounds 1 and 4 belong to a previously
characterized thiazole scaﬀold, but it should be noted that both
A1- and A3AR-selective compounds bearing this group have
been discovered.34,35 In fact, none of the discovered selective
fragments would have been expected to be A3AR-speciﬁc on
the basis of the Ki value of the closest ligand (Table S2). The
known AR ligand closest to compound 1 (Tc = 0.40) was
selective for the A1AR (rat, 0.039 μM) over the A3AR (human,
42% at 1 μM).36 Furthermore, the ChEMBL ligand most
similar to compound 2 was a very close analogue of our
reference ligand, the highly selective A1AR antagonist DPCPX
(Figure S4). Finally, it should be noted that the use of ligand-
guided homology modeling did not appear to bias the docking
screen, as none of the discovered compounds belonged to the
class of A3AR-speciﬁc pyrazolotriazolopyrimidines
37 that
constituted the main selective scaﬀold used to guide model
selection (Figure 2a).
Fragment-to-Lead Optimization. Although the successful
identiﬁcation of fragment ligands for the A3AR was
encouraging, a requisite for successful FBLD is the optimization
of these in terms of selectivity and potency.1 Fragment-to-lead
optimization was guided by the receptor models and focused
on the structure−activity relationship (SAR) for the two most
potent and selective fragments, 1 and 2. Five analogues of
compound 1 and six of compound 2 were tested at the A3- and
A1AR in the ﬂuorescence-based competition binding assay
(Tables 2 and 3).
Compound 1 had a Ki value of 120 nM (LE = 0.62 kcal
mol−1 atom−1) and was predicted to target two nonconserved
regions in the A3AR binding pocket. The cyclopropyl group
occupied the pocket created by Ser2476.52 in the A3AR model
(His2516.52 for the A1AR), whereas the furan ring was
positioned in the hydrophobic cleft formed by Val1695.30,
Ile2536.58, and Leu2647.35 (Figure 3a). These two groups were
connected via a 1,3-thiazole-2-carboxamide moiety, which
formed hydrogen bonds to Asn2506.55 and π-stacking
interactions with Phe1685.29. Despite the fact that this ligand
has only 16 heavy atoms, 29-fold selectivity was observed
experimentally. Compound 22 was ﬁrst evaluated to assess the
role of the furan group, which extended into the nonconserved
hydrophobic pocket in the top of the orthosteric site. The
predicted binding mode of compound 22 suggested that the
slightly smaller substituent would not access the nonconserved
pocket to the same extent as compound 1 (Figure 4a). The
signiﬁcant loss of A3AR aﬃnity and speciﬁcity for compound 22
supported the importance of the furan group (Table 2). To
further optimize the ligand from a fragment to a lead-like
compound, commercially available analogues with larger
substituents were docked to the A3AR model. Compound 23,
with a benzothiophene group replacing the furan, extended
further into the hydrophobic pocket at the top of the A3AR
orthosteric site (Figure 4b). In agreement with this observation,
this ligand was 3-fold more potent at the A3AR, which resulted
in an overall 100-fold selectivity for this subtype (Table 2 and
Figure 5a). Focus was then put on optimizing interactions in
the nonconserved regions in the bottom of the A3AR binding
site, which was predicted to accommodate the cyclopropyl
group. In compounds 24 and 25, the cyclopropyl-substituted
Table 2. Binding Aﬃnities for Analogues of Compound 1; Ki Values Were Obtained from the Fluorescence-Based Competition
Binding Assay in Cells Expressing the A3AR or A1AR
aValues represent mean ± SEM from n separate experiments performed in duplicate. bFold selectivity represents the Ki value at the A1AR divided by
the Ki value at the A3AR.
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thiazole is replaced by 5,6-dihydro-4H-cyclopentathiazole and
benzothiazole groups, respectively. Interestingly, these ligands
displayed >10-fold lower aﬃnity for the A3AR compared with
the parent compound, leading to a loss of selectivity (Table 2).
Analysis of the docking poses suggested that the bicyclic
substituents did not penetrate as deep as the cyclopropyl group
into the nonconserved pocket below Asn2506.55 of the A3AR
(Figures 4 and S8). Instead of reverting to the more potent
cyclopropyl group, we evaluated compound 26, which was
predicted to position a methoxy group in the same pocket. This
analogue restored the aﬃnity (Ki = 120 nM) and improved the
selectivity (34-fold) toward the A3AR (Figure 4c and Table 2).
Overall, 3-fold improvements of potency and selectivity were
achieved in the optimization, and the most promising lead was
compound 23, which had a Ki value of 40 nM and >100-fold
selectivity for the A3AR over the A1AR (Figure 4d).
Compound 2 was the most promising fragment in terms of
selectivity and also had a high LE (0.47 kcal mol−1 atom−1). On
the basis of its predicted binding mode, the selectivity appeared
to originate from the pyrrolidine ring in the nonconserved
pocket at the opening of the A3AR binding site (Figure 3b). To
investigate the contribution of this substituent to the selectivity,
an analogue that lacked this group (compound 27) was
evaluated. As anticipated, this fragment lost a majority of its
selectivity (Table 3). Our models thus suggested that both
compounds 1 and 2 achieved their selectivity by interacting
with residues in the same nonconserved subpocket (Figure 2).
This led us to hypothesize that the SAR for analogues of
compound 1 may be transferable to this scaﬀold. On the basis
of this observation, the pyrrolidine was replaced by a furan
group in compound 28, which docked well into the A3AR
model (Figure S9a). Compound 28 displayed 5-fold-improved
potency at the A3AR and remained strongly selective for this
subtype (Table 3 and Figure 5b). Compounds 29 and 30 were
then tested to further investigate the SAR for substituents at the
same position. Increasing the size of the substituent to a
pyridine in compound 29 led to a 4-fold loss of A3AR aﬃnity
compared with compound 28, which decreased the selectivity,
while reducing the size to a nonplanar cyclopropyl moiety in
compound 30 retained signiﬁcant speciﬁcity toward the A3AR
(70-fold) (Table 3). Focus was then put on further exploring
the SAR for the most promising fragment, compound 28, by
evaluating analogues that retained the furan moiety. Compound
31 maintained its aﬃnity at the A3AR but was also 30-fold more
Table 3. Binding Aﬃnities for Analogues of Compound 2; Ki Values Were Obtained from the Fluorescence-Based Competition
Binding Assay in Cells Expressing the A3AR or A1AR
aValues represent mean ± SEM from n separate experiments performed in duplicate. bFold selectivity represents the Ki value at the A1AR divided by
the Ki value at the A3AR.
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Figure 4. Fragment-to-lead optimization. (a−c) Predicted binding modes for analogues of the most potent fragment (compound 1) from the initial
screen: (a) compound 22 and compound 1 (transparent magenta carbon atoms); (b) compound 23; (c) compound 26. The backbone atoms of the
A3AR are shown as a white cartoon, whereas carbon atoms of key residues are shown as white sticks. Unless noted otherwise, the ligand atoms are
shown as sticks with carbon atoms in orange, and A1AR residues are shown as sticks with cyan carbon atoms (d) Schematic representation of
structure-guided fragment-to-lead optimization based on the homology models of the A3AR (black line outlining the binding site) and A1AR
(transparent cyan highlighting relevant diﬀerences between the target and antitarget). From left to right: compounds 22, 1, 23, and 26.
Figure 5. Concentration response curves for the most selective ligands. (a, b) High content screening images from A3AR and A1AR cells treated with
increasing concentrations of (a) 23 or (b) 28 in the presence of 25 nM CA200645. Images represent CA200645 ﬂuorescence and are representative
of those obtained in four separate experiments. (c, d) Competition binding curves generated from the resulting levels of ﬂuorescence from cells
expressing the A3AR (black circles) or A1AR (red squares) upon treatment with increasing concentrations of (c) 23 or (d) 28 in the presence 25 nM
CA200645. Each data point represents the mean ± SEM from four separate experiments performed in duplicate.
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potent at the A1AR, which signiﬁcantly reduced the selectivity
(Table 3). Similarly, compound 32, which was evaluated in
order to extend further toward the second nonconserved
pocket around Ser2476.52, was almost equally potent at both
subtypes (Table 3). These results supported the conclusion
that in addition to the furan group, the ethyl substituent of
compound 28 was also important for A3AR speciﬁcity. This
further demonstrated that eﬀects on the selectivity due to
substituents at one position can strongly depend on
substituents at other positions of a fragment ligand, which is
in line with observations made for analogues of compound 1.
This could be due to the ability of certain substituents to
anchor the core scaﬀold of a fragment in a particular
orientation, resulting in selectivity when nonconserved binding
site regions are targeted by other substituents. However, in the
absence of such an anchoring group, selectivity gained by the
other substituent could be reduced or ablated because the
fragment can reorient in the binding site. Visual inspection of
the docking poses for compounds 28 and 31 further supported
this hypothesis. In contrast to the selective parent compound
28, compound 31 could be better accommodated in seven out
of the 10 A1AR models (and equally well in the remaining
three), as judged by key interactions with Asn6.55. Anchored by
the ethyl substituent, the orientation of compound 28 appeared
to be more restricted in the A1AR binding site, whereas
compound 31 was able to reorient in response to the subtle
change in chemical structure (Figure S9). Overall, the best
ligand emerged from optimization of interactions in the
nonconserved cavity at the top of the binding site, and despite
the fact that compound 28 was still fragment-sized, it had
submicromolar aﬃnity with >100-fold A3AR selectivity.
To further probe the selectivity proﬁles of our discovered
ligands, the two most promising leads, compounds 23 and 28,
and the fragment ligands from which they were derived,
compounds 1 and 2, were evaluated in radioligand binding
assays at the A2AAR. Compounds 1, 2, and 28 did not show any
signiﬁcant displacement of the radioligand at 10 μM, whereas
compound 23 was determined to have a Ki value of 2.9 μM,
resulting in 72-fold selectivity for the A3AR over the A2A
subtype. All four of these compounds were thus selective for
the A3AR over both the A1 and A2A subtypes.
Functional Assays for Compounds 23 and 28. As the
A3AR homology model was based on a crystal structure
determined in an inactive state and a recent study
demonstrated that commercial screening libraries are biased
toward AR antagonists over agonists,38 we expected the
discovered ligands to behave as antagonists. This was conﬁrmed
by evaluating the functional behavior of our most promising
leads, compounds 23 and 28, for their ability to antagonize 5′-
N-ethylcarboxamidoadenosine (NECA)-mediated internaliza-
tion of the A3AR linked to yellow ﬂuorescent protein (YFP).
Both ligands caused a rightward shift in the agonist-mediated
concentration response curve (Figure 6) with no increase in
internalization at low NECA concentrations, indicating
competitive antagonism. From these shifts, the aﬃnities
(pKD) of the antagonists 23 and 28 were estimated to be
6.13 ± 0.01 and 6.13 ± 0.08 (mean ± SEM, n = 5),
respectively.
■ DISCUSSION
Three key results emerge from our study. Fragment ligands
were ﬁrst successfully identiﬁed on the basis of molecular
docking screens against a homology model of the A3AR. Eight
out of the 21 predicted ligands were veriﬁed to bind in a live-
cell environment using ﬂuorescent ligand assays, corresponding
to a high hit rate of 38%, and several fragments had high
aﬃnities. The second and perhaps most important ﬁnding in
this work is that an additional screen against homology models
of an antitarget could be used to bias the screen toward the
identiﬁcation of subtype-selective fragments. Despite the low
Figure 6. Functional antagonism of the A3AR by compounds 23 and 28. (a) Representative images of CHO cells expressing A3-YFP were treated
with 10 μM 23 or 28 and 1 μM NECA. Clear internalization of A3-YFP upon NECA treatment can be seen, and this is blocked in the presence of 23
or 28. (b) Concentration response curves from A3-YFP-expressing cells treated with increasing concentrations of NECA in the presence (red
squares) or absence (black circles) of 10 μM 23 or 28. Granule count was estimated from the resulting images obtained on the ImageXpress confocal
plate reader. Each data point represents the mean ± SEM of ﬁve experiments performed in triplicate.
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molecular complexity of the screened fragments, six of the eight
discovered ligands were selective for the A3AR over the A1AR,
and several displayed remarkably large diﬀerences in potency.
Finally, the homology models contributed to an understanding
of the structural basis for the selectivity and were used to guide
fragment-to-lead optimization.
It could be argued that prediction of fragment ligands should
pose a signiﬁcant challenge to molecular docking algorithms. As
fragments only occupy a fraction of a binding site, they can be
docked in a large number of orientations, and it may be diﬃcult
for the simpliﬁed scoring function to rank these by aﬃnity.
Despite these shortcomings of docking, the ﬁrst virtual screens
of fragment libraries against GPCR crystal structures have been
successful, reaching hit rates as high as 73% for the H1
histamine receptor.14,15 The high hit rates achieved in these
studies partly reﬂect the druggability of the orthosteric sites of
GPCRs and favorable library bias,39 making these targets
particularly suitable for fragment screening. In addition to the
higher hit rates observed for fragments and the lower
computational cost of the in silico screens, there are other
advantages of focusing on such libraries. For example, as
fragment libraries oﬀer better coverage of chemical space,
docking screens of these may lead to the discovery of
chemotypes that are not present in lead-like libraries.13 The
present study involved additional layers of complexity wherein
fragment ligands were sought to a receptor of unknown
structure and were required to be less potent at a closely related
subtype also lacking a crystal structure. To put our results in
perspective, Stoddart et al.5 carried out an empirical screen of
248 fragments against the A3AR using the same ﬂuorescent
binding assay as in this work, which resulted in the discovery of
34 ligands with aﬃnities between 0.4 and 107 μM. The 14% hit
rate from the screen was relatively high compared with other
experimental fragment screens against GPCRs,2,3 and 17 of the
ligands had Ki values of <10 μM. The most potent fragment (Ki
= 360 nM) was also tested for A3AR selectivity and was found
to display similar aﬃnity for the A1AR. The docking screen
carried out here considered a 2000-fold larger library (>0.5
million compounds) but required the experimental evaluation
of only 21 compounds. The eight discovered A3AR ligands
corresponded to a nearly 3-fold higher hit rate, and a larger
fraction of the hits (four compounds) had Ki values of <10 μM.
Notably, the most potent fragment from the docking screen
had a Ki value of 120 nM with 29-fold selectivity for the A3AR.
Overall, the most potent fragments identiﬁed by molecular
docking and those from Stoddart et al. had similar novelty but
did not signiﬁcantly overlap in terms of chemotypes. This result
further supports the conclusion that combining empirical
screens of small libraries with in silico screening of all
commercially available fragments can increase the number
and diversity of starting points for optimization.14,40
Accurate approaches for homology modeling will be required
to fully capitalize on the recent advances in membrane protein
crystallography and may prove to be essential for addressing
key challenges in early-phase drug discovery.41 A particularly
important role of homology models is in structure-based design
of selective ligands, as representative crystal structures for all
receptor subtypes are not available for any human GPCR
family.11 Prospective docking screens against homology models
of GPCRs have to date yielded diﬀerent levels of
success16,22,30,42 and to our knowledge have not previously
involved modeling of both a target and antitarget to drive
structure-based discovery of selective fragments. If a crystal
structure of a receptor closely related to the target is available, it
could be argued that homology models should be suitable for
docking screens because subpockets that are conserved are
likely to be well-described. In such cases, minor discrepancies in
nonconserved regions of the binding site may not inﬂuence the
docking hit rate. On the contrary, structure-based screens for
selective ligands generally involve interactions in regions that
are not conserved, which are diﬃcult to model accurately on
the basis of homology.42,43 This problem was recently
highlighted by the work of Rodriguez et al.,43 which
demonstrated that homology models of the serotonin 5-HT1B
and 5-HT2B receptors lacked the accuracy required to capture
the subtle binding site diﬀerences responsible for subtype
selectivity that were revealed by crystal structures of these
GPCRs. In the light of these results, it was clear that tailored
modeling strategies for both the target and antitarget receptors
would be necessary to predict subtype-selective GPCR ligands.
We used ligand-guided homology modeling to bias the A3AR
model toward a conformation with the ability to recognize
selective scaﬀolds using an approach similar to that of Katritch
et al.23 A unique component of our strategy was a
representation of the antitarget that captured binding site
ﬂexibility by using an ensemble of structures44 optimized to
discriminate between selective and non-A3AR-selective ligands.
Our docking screens against the resulting A3- and A1AR models
led to the discovery of eight fragment ligands, of which six
displayed the desired subtype selectivity. However, despite the
use of 10 diﬀerent antitarget models, two fragment hits were
only marginally more potent at the A3AR than at the A1
subtype, suggesting that additional and more disparate
conformations might need to be considered in order to further
improve predictions of selectivity. Furthermore, we have not
explicitly considered binding site water molecules, which could
play important roles in determining ligand speciﬁcity.45−47 The
use of ligand data to generate the homology models is also a
limitation of our approach, but it should be noted that the
amount of publicly available small-molecule binding data for
GPCRs is increasing rapidly.48 Our approach is highly
automated, and we anticipate that it could be extended to a
large number of GPCR families, including many targets for
which drug discovery has been hampered by adverse eﬀects
caused by oﬀ-target interactions.
Eﬃcient optimization of fragment hits is crucial for the
successful use of FBLD in drug discovery.1,7 The discovery of
several ligands in our screen provided the opportunity to test
whether homology models could guide fragment-to-lead
optimization. Whereas potency (or ligand eﬃciency) is typically
used to prioritize hits from fragment screens,32 opinion is
currently divided regarding whether selectivity should be
considered. It has been argued that selectivity is too challenging
to predict and that this property may be lost (or gained) in
fragment-to-lead optimization.49 As previously observed for
kinases,49 a complex SAR was observed in the optimization of
selectivity, and small structural changes greatly aﬀected the
speciﬁcity, which may reﬂect the fact that fragments can
reorient in the binding site during optimization to a larger
extent than leads.50 This likely makes rational optimization
more challenging for fragment ligands than for lead- or drug-
like molecules. Encouragingly, we found that the associated
diﬀerences in selectivity could be explained by the homology
models in several cases and guide further optimization. Our
results suggest that selectivity can be a valuable property of hits
from fragment screens provided that the structural basis of
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ligand binding is understood and systematically utilized to
guide optimization. For two selective fragments identiﬁed in
our screen, the chemical groups responsible for the subtype
selectivity were ﬁrst predicted on the basis of modeled
receptor−fragment complexes and subsequently conﬁrmed
experimentally by evaluating analogues lacking those moieties.
Compounds that further exploited nonconserved pockets were
then identiﬁed using docking to the A3AR models, which led to
the discovery of potent lead compounds with >100-fold
selectivity and up to 40 nM aﬃnity for the A3AR. Interestingly,
the two optimized leads, compounds 23 and 28, and the
fragments from which they were derived were also selective for
the A3AR over the A2AAR, which may reﬂect binding site
similarities between the A1 and A2A subtypes.
■ CONCLUSIONS
The main ﬁnding of this work is that docking screens against
homology models of GPCRs can be utilized to discover
subtype-selective fragments. The structural understanding of
ligand selectivity gained from the homology models can also be
used to guide fragment-to-lead optimization. The described
strategy for in silico FBLD for GPCRs of unknown structure
can be readily extended to a large number of pharmaceutically
important targets.
■ METHODS
Sequence Alignment and Homology Modeling. The
sequences of the human A3- and A1AR were aligned to that of the
template crystal structure, the human A2AAR, using PROMALS3D.
51
The sequence alignment was manually edited in loop regions. The C-
and N-terminals and the third intracellular loop were excluded from
the modeling because they were missing in the template structure.
Homology modeling of the human A3AR and A1AR was performed on
the basis of a 1.8 Å resolution structure of the A2AAR (PDB accession
code 4EIY21) using MODELER version 9.11.52 A total of 1000 models
were generated for each receptor. Additional dihedral restraints were
placed on the conserved Asn6.55 to keep the rotamer of this residue
close to that observed in a majority of the available A2AAR crystal
structures. For the A3AR, restraints were placed on the side-chain
rotamer of nonconserved Ser2476.52 to keep it similar to the template
and the distance between residues Arg1735.34 and Asp1755.36 to
prevent these residues from blocking the orthosteric site. For the
A1AR, additional dihedral and distance restraints were placed on
Glu1725.30 and His2646.66 to maintain the salt bridge observed in the
template crystal structure of the A2AAR and on Lys265
6.67 to prevent it
from blocking the orthosteric site.
Ligand-Guided Homology Modeling and Molecular Docking
Screening. All of the docking calculations were carried out with the
program DOCK3.6.26 Unless stated otherwise, the protonation states
of the ionizable residues Asp, Glu, Arg, and Lys in the binding site
were set to their most probable states in the receptor at pH 7.
Histidine tautomeric states in the binding site were set on the basis of
the hydrogen-bonding network. His2516.52, His2646.66, and His2787.43
in the A1AR were protonated at Nε, both side-chain nitrogens, and Nδ,
respectively. Of these, only His2727.43 was also present in the A3AR
and was protonated in the Nδ position. The ﬂexible ligand sampling
algorithm in DOCK3.626 superimposes atoms of the docked molecule
onto binding site matching spheres, which indicate putative ligand
atom positions. A total of 45 matching spheres were used and were
based on the atoms of the cocrystallized antagonist ZM241385. The
spheres were also labeled for chemical matching based on the local
receptor environment.53 The degree of ligand sampling was
determined by the bin size, bin size overlap, and distance tolerance.
These three parameters were set to 0.4 Å, 0.2 or 0.3 Å, and 1.5 Å,
respectively, for both the binding site matching spheres and the
docked molecules. An initial ﬁlter discarded conformations that had
more than one overlapping heavy atom with the receptor. An overlap
between two atoms was deﬁned as a distance shorter than 2.3 or 2.6 Å
for polar or nonpolar atoms, respectively, and was determined from a
precalculated grid. For ligand conformations passing this steric ﬁlter, a
physics-based scoring function was used to evaluate the ﬁt to the
binding site. For the best-scoring conformation of each docked
molecule, 100 steps of rigid-body minimization were carried out. The
score for each conformation was calculated as the sum of the
receptor−ligand electrostatic and van der Waals interaction energies,
corrected for ligand desolvation. These three terms were evaluated
from precalculated grids. The three-dimensional map of the electro-
static potential in the binding site was prepared using the program
Delphi.54 In this calculation, partial charges from the united-atom
AMBER force ﬁeld55 were used for all receptor atoms except the side-
chain amides of Asn2506.55 and Asn2546.55 for the A3AR and A1AR,
respectively, for which the dipole moment was increased to favor
hydrogen bonding to this residue, as described previously for the
A2AAR.
14,39 The program CHEMGRID was used to generate a van der
Waals grid based on a united-atom version of the AMBER force ﬁeld.55
The desolvation penalty for a ligand conformation was estimated from
a precalculated free energy for transfer of the molecule between
solvents with dielectric constants of 78 and 2. The desolvation energy
was obtained by weighting the transfer free energy with a scaling factor
that reﬂects the degree of burial of the ligand in the receptor binding
site.27
Sets of lead-like ligands (molecular weight <350) for the A3AR and
A1AR were extracted from the CHEMBL14 database
48 and consisted
of 520 and 622 compounds, respectively. The set of 138 subtype-
selective ligands of the A3AR (molecular weight <500, >50-fold
selective for the A3AR over the A1 subtype) was extracted from
CHEMBL14.48 Decoys were generated in a 1:50 ratio for each of the
three ligand sets using the DUD-E approach.25 In the prospective
screens, the ZINC fragment library29 of 504 973 commercially
available compounds (molecular weight ≤250, LogP ≤ 3.5, and ≤5
rotatable bonds) was used. All of the docked compounds were
prepared for docking using the ZINC database protocol.29
Similarity Calculations. Similarity calculations for the fragments
were carried out using the Screenmd program from Chemaxon.56 We
calculated the maximum Tanimoto coeﬃcient with ECFP4 ﬁnger-
prints between each discovered fragment ligand and all compounds
that have been annotated against any AR subtype in the ChEMBL20
database.48
Materials. The fragment hits from the initial screen and the
analogues of compounds 1 and 2 were purchased from Enamine, Life
Chemicals, VitasM, Peakdale, Chembridge, and UK organic synthesis
(Table S3). Compound identities and purities were conﬁrmed by
NMR and liquid chromatography−mass spectrometry (LC−MS) for
all discovered ligands (Table S3). FCS was purchased from PAA
Laboratories (Wokingham, UK) and L-glutamine from Lonza (Basel,
Switzerland). MRS1220, DPCPX, and NECA were obtained from
Tocris Bioscience (Bristol, UK). CA200645 was purchased from
Cellaura Technologies Ltd. (Nottingham, UK). All other chemicals
and reagents were purchased from Sigma-Aldrich (Gillingham, UK).
Cell Lines and Cell Culture. Chinese hamster ovary (CHO) cells
expressing the A1AR
57 and CHO CRE-SPAP cells expressing the
A3AR
58 or A3-YFP
59 were prepared as previously described. All of the
cell lines were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) nutrient mix F12 (DMEM-F12) supplemented with 10%
fetal calf serum and 2 mM L-glutamine at 37 °C in a humidiﬁed
atmosphere of air/CO2.
Fluorescence-Based Competition Binding Assay. Cells
expressing the A1AR or A3AR were grown to conﬂuency in the
central 60 wells of a 96-well plate in normal growth medium. Because
of issues with the quality of the images obtained from the outside wells
of a 96-well plate, the outer wells were left blank. On the day of
analysis, the medium was removed and the cells were washed twice
with HEPES-buﬀered saline solution (HBSS; 25 nM HEPES, 10 mM
glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 mM sodium
pyruvate, 1.3 mM CaCl2, 1 mM NaHCO3, pH 7.4). For initial
evaluation of compounds 1−21, a single concentration of test
compound (dependent on the solubility of the individual compound;
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see Figure S5 and Table S1), 1 μMMRS1220, 1 μM DPCPX, or buﬀer
was added in duplicate to the required wells, followed by 25 nM
CA200645. For analysis of the aﬃnities of compounds, increasing
concentrations of the required compounds were added, followed by 25
nM CA200645. Cells were then incubated for 1 h at 37 °C (no CO2)
and then washed once in HBSS prior to imaging on an ImageXpress
Ultra confocal plate reader (Molecular Devices, Sunnyvale, CA, USA).
Four images were taken per well using a Plan Fluo 40× NA0.6 extra-
long working distance objective by excitation of the ﬂuorophore
(BODIPY630/650) at 636 nm, and the emission was collected
through a 640−685 nm band-pass ﬁlter. To obtain the total image
intensity a modiﬁed multiwavelength cell scoring algorithm within
MetaXpress software (Molecular Devices) was used.
Receptor Internalization Assay. CHO cells expressing A3-YFP
were grown to conﬂuency in the central 60 wells of black-walled, clear
bottom 96-well plates. On the day of the experiment, normal growth
medium was replaced with serum-free medium (DMEM-F12
containing 2 mM L-glutamine) containing, where required, a ﬁxed
concentration of 23 or 28, and the cells were incubated for 30 min at
37 °C/5% CO2/95% air. This was followed by the addition of
increasing concentrations of NECA, and the cells were incubated for a
further 60 min. All of the medium was then removed, and the cells
were washed once in phosphate-buﬀered saline (PBS) prior to ﬁxation
with 3% paraformaldehyde solution in PBS (20 min, room
temperature). The cells were then washed twice in PBS, and the
nuclei were stained by the addition of H33342 (2 μg/mL−1, 20 min,
room temperature). The cells were washed a further two times and
then imaged on the ImageXpress Ultra confocal plate reader. Four
central images were taken per well using a Plan Fluor 40× NA0.6
extra-long working distance objective. YFP images were obtained by
excitation at 488 nm, and the emission was collected through a 525−
550 nm band-pass ﬁlter. H33342 was imaged by excitation at 405 nm
and emission collection through a 447−460 nm band-pass ﬁlter.
Analysis of the images was carried out using a granularity algorithm
within MetaXpress software (Molecular Devices) to identify the
granule count per cell on a per-image basis. A3-YFP granules were
classiﬁed as having a diameter of between 7 and 15 μm and cell nuclei
between 6 and 9 μm, with the intensity above background set for each
individual experiment.
Data Analysis. All of the concentration−response data were ﬁtted
using nonlinear regression models with Prism 6 (GraphPad Software,
San Diego, CA, USA). Competition binding curves were ﬁtted to the
following equation to obtain the binding aﬃnity (Ki) of the unlabeled











where [L] is the concentration of CA200645 used (25 nM) and KD is
the aﬃnity (in nM) of CA200645 at the A1AR or A3AR. The
calculated KD values used were 17.0 nM at the A1AR and 3.11 nM at
the A3AR. The IC50 was calculated using the following equation:
= ×
+
% inhibition of specific binding
100 [A]
[A] IC50
where [A] is the concentration of the competing drug and the IC50 is
the molar concentration of ligand required to inhibit 50% of the
speciﬁc binding of 25 nM CA200645. Concentration−response









where Emax is the maximal response in the absence of competing ligand
and the EC50 is the molar concentration of agonist required to
generate 50% of the Emax. This was followed by estimation of the






where the dose ratio (DR) is the ratio of the agonist (NECA)
concentrations required to stimulate an identical response in the
presence and absence of the antagonist, B.
Radioligand Binding Assays for the A2AAR. The aﬃnities of the
four compounds 1, 2, 23, and 28 were obtained at the human A2AAR
in vitro using radioligand binding assays according to experimental
protocols described elsewhere.60 Human A2AAR expressed in trans-
fected HeLa cells was employed, and [3H]-ZM241385 was used as the
radioligand. Binding was evaluated as a percentage of the inhibition
value at a single-point concentration of 10 μM or the Ki value for
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